Use of stereotactic body radiotherapy for prostate cancer in the United States from 2004 through 2012

Cancer

Volumn 122, Issue 14, 2016, Pages 2234-2241

  Baker, Brock R ^a   Basak, Ramsankar ^a   Mohiuddin, Jahan J ^a   Chen, Ronald C ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

diffusion of technology; National Cancer Data Base; prostate cancer; radiotherapy modalities; stereotactic body radiotherapy (SBRT)

Indexed keywords

ADULT; AGED; ARTICLE; CANCER REGISTRY; COMMUNITY PROGRAM; CONTROLLED STUDY; HIGH RISK PATIENT; HUMAN; INTERMEDIATE RISK PATIENT; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; PATIENT CODING; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROSTATE CANCER; STEREOTACTIC BODY RADIATION THERAPY; UNITED STATES;

EID: 84977545135     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30034     Document Type: Article

References (28)

1. Mohler JL, Kantoff PW, Armstrong AJ, et al; National Comprehensive Cancer Network. Prostate cancer, version 2.2014. J Natl Compr Canc Netw. 2014;12:686–718.
2. Sheets NC, Goldin GH, Meyer AM, et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA. 2012;307:1611–1620.
3. Ceylan C, Kucuk N, Bas Ayata H, Guden M, Engin K. Dosimetric and physical comparison of IMRT and CyberKnife plans in the treatment of localized prostate cancer. Rep Pract Oncol Radiother. 2010;15:181–189.
4. Yu JB, Cramer LD, Herrin J, Soulos PR, Potosky AL, Gross CP. Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity. J Clin Oncol. 2014;32:1195–1201.
5. Mangoni M, Desideri I, Detti B, et al. Hypofractionation in prostate cancer: radiobiological basis and clinical appliance. Biomed Res Int. 2014;2014:781340.
6. Tree AC, Alexander EJ, Van As NJ, Dearnaley DP, Khoo V. Biological dose escalation and hypofractionation: what is there to be gained and how will it best be done? Clin Oncol (R Coll Radiol). 2013;25:483–498.
7. Gomez-Millan J, Lara MF, Correa Generoso R, Perez-Rozos A, Lupianez-Perez Y, Medina Carmona JA. Advances in the treatment of prostate cancer with radiotherapy. Crit Rev Oncol Hematol. 2015;95:144–153.
8. Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15:683–690.
9. Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys. 2007;67:1099–1105.
10. King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC Jr. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys. 2009;73:1043–1048.
11. Boike TP, Lotan Y, Cho LC, et al. Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol. 2011;29:2020–2026.
12. Parsons JK, Messer K, Palazzi K, Stroup SP, Chang D. Diffusion of surgical innovations, patient safety, and minimally invasive radical prostatectomy. JAMA Surg. 2014;149:845–851.
13. Mantz C, E F. Real-time target tracking prostate SBRT and the real-time tracking system 4D localization system: 5-year quality of life and disease outcomes. Int J Radiat Oncol Biol Phys. 2013;87:S393.
14. Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol. 2011;6:3.
15. Katz AJ, Kang J. Stereotactic body radiotherapy as treatment for organ confined low- and intermediate-risk prostate carcinoma, a 7-year study. Front Oncol. 2014;4:240.
16. King CR, Freeman D, Kaplan I, et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol. 2013;109:217–221.
17. American College of Surgeons. Cancer program categories. https://www.facs.org/quality-programs/cancer/accredited/about/categories. Accessed June 8, 2015.
18. Nguyen PL, Gu X, Lipsitz SR, et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol. 2011;29:1517–1524.
19. Cobran EK, Chen RC, Overman R, et al. Racial differences in diffusion of intensity-modulated radiation therapy for localized prostate cancer [published online ahead of print February 5, 2015]. Am J Mens Health. pii: 1557988314568184.
20. Parthan A, Pruttivarasin N, Davies D, et al. Comparative cost-effectiveness of stereotactic body radiation therapy versus intensity-modulated and proton radiation therapy for localized prostate cancer. Front Oncol. 2012;2:81.
21. Chen LN, Suy S, Uhm S, et al. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol. 2013;8:58.
22. King CR, Brooks JD, Gill H, Presti JC Jr. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82:877–882.
23. Loblaw A, Cheung P, D'Alimonte L, et al. Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes. Radiother Oncol. 2013;107:153–158.
24. King CR, Collins S, Fuller D, et al. Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials. Int J Radiat Oncol Biol Phys. 2013;87:939–945.
25. Meyer AM, Wheeler SB, Weinberger M, Chen RC, Carpenter WR. An overview of methods for comparative effectiveness research. Semin Radiat Oncol. 2014;24:5–13.
26. Meier R. Dose-escalated robotic SBRT for stage I-II prostate cancer. Front Oncol. 2015;5:48.
27. Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 2002;53:1111–1116.
28. Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol. 2006;176(4 pt 1):1415–1419.